[
  {
    "question": "PET, Dx:",
    "option_a": "(FTD) is correct because the characteristic PET pattern\u2014frontal and anterior temporal hypometabolism\u2014is typical for FTD. Option B (AD) is incorrect because Alzheimer\u2019s disease generally shows hypometabolism in the temporoparietal and posterior cingulate cortices. Option C (DLB) does not fit because Dementia with Lewy Bodies typically has occipital hypometabolism. Option D (PD) is also incorrect, as Parkinson\u2019s disease without dementia rarely shows such a marked cortical pattern, and when dementia is present, the pattern differs from that seen in FTD.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Dementia",
    "explanation": "Positron Emission Tomography (PET) imaging, specifically FDG-PET, is used in the evaluation of dementia. Different dementias have characteristic patterns of hypometabolism. Frontotemporal Dementia (FTD) shows predominant involvement of the frontal and anterior temporal lobes, which correlates with its clinical presentation. FTD is characterized by the degeneration of neurons predominantly in the frontal and anterior temporal regions. This neurodegeneration is associated with abnormal protein accumulations (such as tau or TDP-43) and leads to decreased glucose metabolism in these areas on FDG-PET imaging. Patients with FTD typically present with behavioral changes such as disinhibition, apathy, or language disturbances. The PET finding of hypometabolism in the frontal and anterior temporal lobes supports the clinical diagnosis and helps distinguish FTD from other dementias like Alzheimer disease, which more commonly affects parietal and posterior cingulate regions. The diagnostic workup for dementia often includes neuroimaging. Differential diagnoses include Alzheimer disease (characterized by temporoparietal hypometabolism), Dementia with Lewy Bodies (which shows occipital hypometabolism), and Parkinson\u2019s disease (in which dementia, when present, usually follows a pattern different from FTD). A careful history and neuropsychological testing help correlate imaging findings with clinical symptoms. There is no disease-modifying treatment for FTD. The management is largely symptomatic and supportive. First-line measures include behavioral interventions, environmental modifications, and caregiver support. Some studies suggest SSRIs may help manage behavioral symptoms. In contexts of pregnancy and lactation (where applicable in younger patients with early FTD), non-pharmacologic interventions should be prioritized and medication risks weighed carefully. Option A (FTD) is correct because the characteristic PET pattern\u2014frontal and anterior temporal hypometabolism\u2014is typical for FTD. Option B (AD) is incorrect because Alzheimer\u2019s disease generally shows hypometabolism in the temporoparietal and posterior cingulate cortices. Option C (DLB) does not fit because Dementia with Lewy Bodies typically has occipital hypometabolism. Option D (PD) is also incorrect, as Parkinson\u2019s disease without dementia rarely shows such a marked cortical pattern, and when dementia is present, the pattern differs from that seen in FTD. 1. FDG-PET is a valuable tool in differentiating dementia subtypes based on regional metabolic patterns. 2. FTD should be suspected in patients with early behavioral and language changes. 3. Alzheimer disease generally spares the frontal lobes in its early stages, unlike FTD. Recent studies continue to refine the imaging criteria for dementia, and recent guidelines support the use of FDG-PET in cases where clinical diagnosis is uncertain. The role of molecular biomarkers is also expanding, further aiding in the differentiation of dementia types.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "A physician is spending time with a patient for unnecessary conversation",
    "option_a": "if such lettering were used.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Unnecessary conversation or excessive, uncontrolled talk is often a sign of disinhibition. In the context of neurological disorders, particularly those involving the frontal lobes (especially the orbitofrontal region), such behavior is recognized as part of an orbitofrontal syndrome. Damage or dysfunction in the orbitofrontal cortex impairs the brain\u2019s ability to modulate social behavior and inhibit inappropriate responses. This disinhibition can manifest as excessive, unfiltered, or unnecessary conversation. Neuroimaging studies have demonstrated a correlation between orbitofrontal damage and these behavioral changes. Clinically, patients with orbitofrontal syndrome may exhibit behaviors such as impulsivity, socially inappropriate remarks, and compulsive communication. These symptoms help differentiate frontal lobe disinhibition from other speech disturbances such as aphasia, which is characterized by impaired language formation or comprehension. The diagnostic workup includes a detailed neuropsychiatric evaluation and neuroimaging (e.g., MRI, PET) to assess the integrity of the frontal lobes. Differential diagnoses include aphasia (dictated by language deficits rather than disinhibition), mania (which includes pressured speech along with elevated mood), and psychotic disorders (where disorganized speech is accompanied by delusions or hallucinations). Management begins with accurately assessing and diagnosing the underlying cause. First-line management may involve behavioral interventions and, in some cases, pharmacotherapy (such as SSRIs) to help reduce disinhibition. In patients who are pregnant or lactating, non-pharmacologic strategies are preferred and any medications used must be carefully selected to minimize fetal and neonatal exposure while still addressing the symptoms. While the original marked answer was indicated as 'N', the correct answer should indicate a syndrome associated with frontal lobe dysfunction (i.e., orbitofrontal syndrome). Options representing aphasia, psychosis, or primary psychiatric disorders are less consistent with the originating pathology of unnecessary conversation driven by disinhibition. Thus, the correct conceptual answer aligns with orbitofrontal syndrome, typically assigned to option A if such lettering were used. 1. Excessive, unnecessary conversation is a hallmark sign of orbitofrontal disinhibition. 2. Always differentiate between language deficits (aphasia) and disinhibited behaviors when assessing speech abnormalities. 3. Frontal lobe dysfunction may manifest subtly; thorough neuropsychiatric evaluation is essential. Recent neuroimaging and neuropsychological studies have reinforced the link between orbitofrontal cortex dysfunction and disinhibited behavior. Current clinical guidelines stress the importance of targeted behavioral interventions, particularly in patients where conventional psychiatric diagnoses do not fully explain the symptomatology.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "You received a call from one of your patients whose living in nursing home informing you that he was physically abused",
    "option_a": "(Ignore the issue) is clearly unacceptable and unethical. Option B (Contact the nursing home) is the correct and immediate step as it sets off the appropriate institutional protocols to investigate and protect the patient. Option C (Inform your senior) is not sufficient as a standalone measure since the priority is to act directly to secure the patient\u2019s safety. Option D (Visit the nursing home yourself) may compromise the investigation and safety of the patient, as unplanned visits could alert the abuser. The marked answer 'T' does not correspond to these action steps; thus, the correct answer is Option B.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Elder abuse is a serious and under-recognized problem, especially in institutional settings like nursing homes. Physicians have a legal and ethical responsibility to take action when abuse is suspected to protect vulnerable patients. Although there is no specific pathophysiological mechanism for abuse, its effects can include physical injury, psychological trauma, and long-term deterioration in health. Recognizing abuse early can prevent further harm and improve outcomes for the patient. Patients residing in nursing homes may be at higher risk for abuse due to factors such as dependency on caregivers, communication difficulties, and cognitive impairments. Prompt recognition and reporting of physical abuse are essential to prevent ongoing harm. When abuse is suspected, a thorough assessment is required that includes physical examination, review of medical records, and possibly imaging to document injuries. Differential considerations include accidental falls or self-inflicted injuries; a careful history and witness statements are important. Other causes (like neglect) should also be considered and ruled out. According to current guidelines, any suspicion of abuse requires immediate intervention. First-line management is to contact the nursing home and initiate an internal investigation and/or alert adult protective services to ensure the patient\u2019s safety. Simultaneously, documenting the findings and reporting the issue formally are critical. In cases involving pregnant or lactating patients in similar vulnerable settings, the same safeguarding and immediate reporting principles apply while ensuring the safety of both the patient and, if applicable, the fetus or neonate. Option A (Ignore the issue) is clearly unacceptable and unethical. Option B (Contact the nursing home) is the correct and immediate step as it sets off the appropriate institutional protocols to investigate and protect the patient. Option C (Inform your senior) is not sufficient as a standalone measure since the priority is to act directly to secure the patient\u2019s safety. Option D (Visit the nursing home yourself) may compromise the investigation and safety of the patient, as unplanned visits could alert the abuser. The marked answer 'T' does not correspond to these action steps; thus, the correct answer is Option B. 1. Elder abuse is a medical emergency and has mandated reporting laws in nearly all jurisdictions. 2. Always document any physical or behavioral signs of abuse, including inconsistencies in the history. 3. Rapid intervention is critical to prevent ongoing harm in vulnerable patient populations. Current guidelines from agencies such as the U.S. Centers for Disease Control and Prevention (CDC) and state regulatory bodies emphasize immediate action upon suspicion of elder abuse. Emerging research also highlights the importance of training healthcare providers in recognizing subtle signs of abuse, especially in high-risk settings like nursing homes.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Alzheimer in young age with, AD inheritance",
    "option_a": "(APP mutation) is incorrect because although APP mutations can cause EOFAD, they are less common than PSEN1 mutations. Option B (APOE4) is incorrect as it is a risk factor for late",
    "option_b": "",
    "option_c": "(Presenilin 1) is correct since PSEN1 mutations are the most frequent cause of familial early",
    "option_d": "(Presenilin 2) is incorrect because PSEN2 mutations, while causative, are much rarer and tend to have later onset and variable penetrance.",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Dementia",
    "explanation": "Early-onset familial Alzheimer\u2019s disease (EOFAD) is a form of Alzheimer\u2019s that appears before the age of 65 and is inherited in an autosomal dominant manner. The core concept is that specific gene mutations lead to abnormal processing of the amyloid precursor protein (APP), and among these, mutations in the Presenilin 1 (PSEN1) gene are the most common cause. PSEN1 is an integral component of the gamma\u2010secretase complex responsible for cleaving APP. Mutations in PSEN1 alter the cleavage process, increasing the production of the amyloid beta 42 (A\u03b242) peptide, which is more prone to aggregation. The accumulation of these toxic amyloid plaques triggers a cascade of neurodegenerative events including tau phosphorylation, neuronal loss, and synaptic dysfunction. Patients with EOFAD typically present with memory impairments at a younger age (often between 40 and 60 years) compared with late-onset AD. Because of the autosomal dominant inheritance pattern, a positive family history is common. The rapid progression of symptoms is also a characteristic feature in PSEN1-associated Alzheimer\u2019s disease. Diagnosis relies on a combination of family history, neuropsychological testing (eg, Mini-Mental State Examination), and neuroimaging techniques (MRI, PET scans) to assess brain atrophy and amyloid deposition. Genetic testing for mutations in PSEN1 (as well as APP and PSEN2) is confirmatory. Differential diagnoses include other early-onset dementias like frontotemporal dementia, vascular dementia, or metabolic disorders. Management is symptomatic and includes the use of cholinesterase inhibitors (eg, donepezil, rivastigmine) and NMDA receptor antagonists (eg, memantine). Although these treatments may alleviate symptoms, they do not alter disease progression. Newer disease\u2010modifying therapies (such as monoclonal antibodies targeting amyloid plaques) are under investigation. In cases of women who are pregnant or lactating, careful risk\u2010benefit analysis and interdisciplinary consultation are necessary before initiating any pharmacotherapy due to potential fetal/neonatal exposure. Option A (APP mutation) is incorrect because although APP mutations can cause EOFAD, they are less common than PSEN1 mutations. Option B (APOE4) is incorrect as it is a risk factor for late-onset Alzheimer\u2019s disease, not a causative mutation in EOFAD. Option C (Presenilin 1) is correct since PSEN1 mutations are the most frequent cause of familial early-onset Alzheimer\u2019s disease. Option D (Presenilin 2) is incorrect because PSEN2 mutations, while causative, are much rarer and tend to have later onset and variable penetrance. 1. PSEN1 mutations are the most common cause of early-onset familial Alzheimer\u2019s disease. 2. A strong family history suggests a genetic form of Alzheimer\u2019s disease. 3. Early-onset Alzheimer\u2019s often progresses more rapidly than late-onset disease. Recent research emphasizes the importance of genetic counseling and early genetic testing for at-risk individuals. Emerging therapies targeting amyloid beta pathology (eg, monoclonal antibodies) are being integrated into treatment paradigms, although their use remains controversial. Current guidelines also stress the supportive management of symptoms and the role of non-pharmacological interventions.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Case of Gerstmann feature what is the associated language deficit",
    "option_a": "anomia",
    "option_b": "Wernicke's aphasia",
    "option_c": "Transcortical motor",
    "option_d": "",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Dementia",
    "explanation": "Gerstmann syndrome is a neuropsychological deficit characterized by a cluster of symptoms that classically include acalculia, agraphia, finger agnosia, and left-right disorientation. The language-related deficit most notably concerns writing (agraphia) rather than naming (anomia). Lesions typically located in the dominant inferior parietal lobule\u2014especially the angular gyrus\u2014disrupt the integration of sensory and cognitive processes. This results in a breakdown of abilities that depend on the parietal region\u2019s role in processing numerical concepts, body schema, and aspects of language like writing. Patients with Gerstmann syndrome often struggle with writing (agraphia) and calculations (acalculia), as the lesion interferes with the higher-order processing required for these tasks. The misinterpretation of the language deficit as anomia (difficulty in word finding) is incorrect; the hallmark is the inability to write properly rather than the inability to name objects. A detailed clinical evaluation including a neuropsychological assessment is essential. Cognitive tests that evaluate writing, calculation, finger recognition, and spatial orientation help localize the lesion. MRI typically demonstrates a lesion in the angular gyrus. Differential diagnoses include other parietal lobe syndromes and conditions that may also affect language (eg, aphasia from stroke involving Broca\u2019s or Wernicke\u2019s areas). Management revolves around treating the underlying cause such as ischemic stroke, tumor, or trauma. Rehabilitation with occupational and speech therapies may help improve functional outcomes. In pregnant or lactating women, a careful evaluation of neuroimaging modalities (favoring MRI without contrast when possible) and management strategies is necessary to minimize fetal or neonatal exposure to potential treatment risks. Option A (anomia) is incorrect because Gerstmann syndrome is characterized by agraphia (impaired writing), not by difficulty in naming objects. Option B (Wernicke\u2019s aphasia) is incorrect as it involves fluent but nonsensical speech with impaired comprehension. Option C (transcortical motor aphasia) is also incorrect because it is characterized by nonfluent speech with intact repetition. The correct answer, which should be provided as Option D, is agraphia. 1. Gerstmann syndrome classically presents with agraphia, acalculia, finger agnosia, and left-right disorientation. 2. The angular gyrus is the key anatomical location implicated in this syndrome. 3. Agraphia is the core language deficit, not anomia. Recent studies using advanced neuroimaging techniques have reinforced the role of the angular gyrus in integrating complex cognitive functions related to writing and calculation. Updated guidelines emphasize the importance of correlating clinical symptoms with lesion location for accurate diagnosis and tailored rehabilitation.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Case of Gerstmann feature where is the lesion:",
    "option_a": "angular gyrus",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Gerstmann syndrome comprises a group of deficits\u2014agraphia, acalculia, finger agnosia, and left\u2013right disorientation\u2014that arise from a lesion in a specific brain region. The angular gyrus, located in the dominant parietal lobe, is the conceptual cornerstone in understanding the syndrome. Lesions in the angular gyrus interfere with the integration of multi-modal sensory information. This disruption affects the neural networks responsible for mathematical processing, recognition of one\u2019s own body parts (finger agnosia), spatial orientation (left-right disorientation), and the ability to write (agraphia). Clinically, patients present with difficulties in writing and calculating, as well as problems with finger recognition and distinguishing left from right. These deficits reflect the localized disruption within the angular gyrus and help in localizing the lesion to this region. A comprehensive evaluation includes neuropsychological tests specifically designed to assess writing, calculation, and spatial orientation. Neuroimaging, especially MRI, is critical to identify lesions in the angular gyrus. Differential diagnoses might include other parietal lobe syndromes, stroke, or tumors that affect similar regions. Management is focused on addressing the underlying cause\u2014for example, acute stroke protocols if a vascular event is identified or surgical intervention if a tumor is present. Rehabilitation, including occupational and speech therapy, plays an important role. In the context of pregnancy or lactation, treatment options must be carefully considered with imaging and interventions tailored to minimize risks. Option A (angular gyrus) is correct because this is the well-established location of the lesion in Gerstmann syndrome. Other options (if present) would not localize as precisely to the constellation of deficits seen in Gerstmann syndrome. 1. The left angular gyrus is typically the site of lesions causing Gerstmann syndrome in right-handed individuals. 2. Recognition of the syndrome\u2019s key features (agraphia, acalculia, finger agnosia, left-right disorientation) is crucial for localization. 3. Neuroimaging is the cornerstone for confirming the diagnosis. New advances in functional MRI and diffusion tensor imaging have enhanced our understanding of parietal lobe connectivity and its role in cognitive integration, reinforcing the association of angular gyrus lesions with Gerstmann syndrome.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Case of prosopagnosia (can\u2019t recognize patient by face but by cue like voice walking and moustache) where is the lesion",
    "option_a": "Inferior occipitotemporal (fusiform gyri in bilateral inferior occipitotemporal lesion)",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Prosopagnosia, or face blindness, is a neurological condition where the affected individual is unable to recognize familiar faces, although they may use other cues (such as voice, gait, or distinctive features like a moustache) for identification. The fusiform gyrus, located in the inferior occipitotemporal region, is the critical area involved in facial recognition. Lesions in the bilateral inferior occipitotemporal cortex, particularly in the fusiform face area, disrupt the neural circuitry responsible for processing facial features. This disruption leads to an impaired ability to form a coherent face percept, while other aspects of visual recognition remain intact. Clinically, patients with prosopagnosia frequently report difficulty in recognizing faces\u2014even those of close friends or family\u2014and may rely on secondary cues such as voice or distinctive physical features. This specific deficit in face recognition helps differentiate prosopagnosia from other visual agnosias. Diagnosis is based on detailed clinical history and neuropsychological testing geared towards assessing facial recognition abilities. Structural and functional neuroimaging (MRI, fMRI) is used to demonstrate lesions in the fusiform gyrus. Differential diagnoses include other visual or cognitive disorders that affect facial processing, such as occipital lobe lesions or certain forms of visual agnosia. There is no specific cure for prosopagnosia; management is largely supportive. Patients may benefit from compensatory strategies such as using contextual cues (voice, clothing, distinctive features) to recognize individuals. In cases where an underlying pathology (eg, stroke, tumor) is identified, addressing the cause may reduce progression. Pregnancy and lactation do not alter the management approach significantly, but supportive therapies and counseling remain important. Option A, referring to a lesion in the inferior occipitotemporal region (specifically the fusiform gyri), is correct because this area is consistently implicated in face processing. Other options would either involve areas that do not process facial recognition or are too vague to explain the selective deficit seen in prosopagnosia. 1. The fusiform face area in the inferior occipitotemporal cortex is essential for face recognition. 2. Prosopagnosia can be either acquired or developmental, with bilateral lesions typically causing the deficit. 3. Patients often compensate by relying on non-facial cues such as voice or distinctive physical characteristics. Recent functional imaging studies have provided deeper insights into the specialized role of the fusiform face area. Research continues to explore rehabilitative strategies and neuroplasticity in prosopagnosia, but to date, treatment remains supportive. Updated clinical guidelines emphasize the importance of accurate lesion localization for prognostication and counseling.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Feature of Wernicke\u2019s encephalopathy what is the type of memory impaired",
    "option_a": "immediate memory",
    "option_b": "Episodic memory",
    "option_c": "Procedural memory",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Wernicke\u2019s encephalopathy is an acute neurological disorder due to thiamine (vitamin B1) deficiency, most often seen in chronic alcohol abusers but also in other malnourished states. In its evolution to Korsakoff syndrome, patients develop significant memory deficits, particularly affecting the declarative or explicit memory systems that include episodic memory. Thiamine deficiency leads to selective damage in regions of the brain such as the mammillary bodies, thalamic nuclei (especially the dorsomedial nucleus), and periaqueductal gray matter. This damage disrupts the neural circuits involved in memory consolidation and retrieval. As a result, patients have trouble forming new memories (anterograde amnesia) and retrieving previously experienced events, which is characteristic of an impairment in episodic memory. Clinically, patients initially present with the classic triad of confusion, ophthalmoplegia, and ataxia (Wernicke\u2019s encephalopathy). If untreated, the syndrome may evolve into Korsakoff syndrome, where the most prominent deficit is the loss of episodic memory, often with preserved immediate (working) memory and intact procedural memory. This means patients may be able to perform learned tasks despite not remembering learning the task. Diagnosis is primarily clinical, supported by imaging (MRI may show symmetrical lesions in the thalamus and mammillary bodies) and laboratory findings (low thiamine levels). Differential diagnoses include other causes of amnesia such as Alzheimer\u2019s disease or vascular dementia. Their memory deficits differ in that Alzheimer\u2019s typically affects both episodic and semantic memory and vascular causes usually have a stepwise decline. Immediate treatment with intravenous thiamine is critical to reverse the acute symptoms and prevent progression to irreversible Korsakoff syndrome. Thiamine should be administered before any carbohydrate load. In pregnancy and lactation, thiamine supplementation is safe and is particularly important as both mother and fetus can be affected by deficiency. Option A (immediate memory) is not ideal because while working memory might be affected in severe cases, the hallmark impairment in Wernicke-Korsakoff syndrome is in forming and retrieving episodic memories. Option C (procedural memory) is typically spared in these patients. Therefore, Option B (episodic memory) is the most appropriate answer. 1. Korsakoff syndrome, the chronic phase of the disease, is most notable for its profound anterograde amnesia affecting episodic memory. 2. Rapid thiamine replacement is essential to prevent permanent neurological damage. Recent guidelines emphasize early recognition and treatment of thiamine deficiency to prevent irreversible brain damage. Neuroimaging findings continue to support the role of thiamine in maintaining the integrity of memory circuits, and research underscores that prompt intervention is the key to better outcomes.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Another similar image (PET scan) change habit to sweet dx",
    "option_a": "FTD",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Frontotemporal dementia (FTD) encompasses a group of neurodegenerative disorders that primarily affect the frontal and temporal lobes. The behavioral variant of FTD often manifests with disinhibition, compulsive behaviors, and changes in dietary preferences, such as an increased craving for sweets. FTD is characterized by degeneration of the frontal and anterior temporal lobes. This degeneration leads to disruption in the neural circuits that regulate behavior, social norms, and appetite. The orbitofrontal cortex, in particular, plays a key role in modulating reward and impulse control, accounting for the increased preference for sweets and other altered eating behaviors observed in these patients. Clinically, patients with FTD may present with marked personality changes, disinhibition, apathy, and compulsive or altered eating behavior. The change in dietary habits toward sweets is a common and distinguishing feature, especially in the behavioral variant of FTD, helping differentiate it from other dementias that predominantly present with memory impairment, such as Alzheimer\u2019s disease. Diagnosis is made through a combination of detailed clinical history, neuropsychological testing, and neuroimaging. PET scans or FDG-PET imaging reveals hypometabolism in the frontal and/or temporal lobes, supporting the diagnosis. Differential diagnoses include Alzheimer\u2019s disease (which typically shows prominent memory deficits and occipital hypometabolism) and vascular dementia. Management of FTD is primarily supportive and symptomatic. There is no disease-modifying therapy available at present. Non-pharmacologic interventions, behavioral modification strategies, and, in some cases, selective serotonin reuptake inhibitors (SSRIs) can be used to manage disinhibited behaviors. In cases where pharmacotherapy is considered in pregnancy or lactation, careful evaluation of risks versus benefits is essential, with preference given to non-pharmacological strategies when possible. Option A (FTD) is correct because the described behavioral changes (including altered food preference toward sweets) and PET imaging findings of frontal hypometabolism are classic for FTD. The other options, although not listed, would include conditions that do not typically present with these specific behavioral changes. 1. A sudden change in dietary habits, such as an increased craving for sweets, can be a red flag for FTD. 2. Behavioral variant FTD usually presents with early and prominent personality changes rather than memory loss. Recent studies reinforce the use of PET imaging in the early detection of FTD, particularly by highlighting the regional hypometabolism patterns. Current research also focuses on behavioral interventions and the potential future role of targeted therapies in modifying disease progression.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with apathy and cerebral atrophy with change in eating habit, attached imaging of PET and brain MRI showing decrease metabolism in frontal and temporal lobe with atrophy, in the left frontal lobe what is the diagnosis",
    "option_a": "FTD",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "This clinical scenario describes a patient with apathy, behavioral changes (including altered eating habits), and neuroimaging findings of frontal and temporal lobe atrophy\u2014particularly in the left frontal lobe. These features are strongly indicative of frontotemporal dementia (FTD), especially its behavioral variant. FTD involves the progressive degeneration of the frontal and temporal lobes, leading to impaired executive function, personality changes, and disinhibition. The left frontal lobe is crucial for aspects of behavior regulation and language, and its atrophy explains symptoms like apathy and changes in eating habits. The underlying pathology often involves tau protein accumulation or TDP-43 proteinopathy. Patients with FTD typically present with marked personality changes, such as apathy, loss of empathy, and alterations in social conduct, along with behavioral disinhibition like abnormal eating habits. The neuroimaging findings of atrophy and hypometabolism in the frontal and temporal lobes further solidify the diagnosis. The diagnosis relies on a combination of clinical evaluation, neuropsychological testing, and neuroimaging studies (MRI and PET). Differential diagnoses include Alzheimer\u2019s disease, which more commonly presents with memory deficits rather than early behavioral changes, and vascular dementia, which may have a more stepwise clinical progression. There is no cure for FTD; management is symptomatic and supportive. Behavioral symptoms can sometimes be managed with SSRIs or other mood stabilizers. Non-pharmacologic interventions such as caregiver education, structured routines, and speech/language therapy may also be beneficial. When managing similar cases in younger patients (or in the rare scenario of early-onset FTD in a woman who is pregnant or lactating), the risk\u2013benefit profile of any pharmacologic interventions must be carefully considered, with a strong preference for non-drug approaches when feasible. Option A (FTD) is correct because the combination of apathy, altered eating behavior, and neuroimaging showing left frontal and temporal lobe involvement is characteristic of frontotemporal dementia. Other potential differentials like Alzheimer\u2019s disease would more prominently feature memory deficits rather than isolated behavioral changes. 1. Behavioral variant FTD is characterized by early personality changes and disinhibition rather than the memory impairment seen in other dementias. 2. PET imaging showing frontal and temporal hypometabolism is a key diagnostic feature. Current research underlines the importance of early imaging in FTD diagnosis and continues to explore potential biomarkers. Although disease-modifying treatments are not yet available, recent studies emphasize multidisciplinary management strategies to improve patient and caregiver quality of life.",
    "exam_year": "2019",
    "exam_type": "Part I",
    "image_url": "page_14.png"
  },
  {
    "question": "Same as previous imaging showing with FTD but with agrammatic aphasia what is the diagnosis",
    "option_a": "?? I forgot",
    "option_b": ") is correct if it represents this diagnosis, as Option A (which is unclear, 'I forgot') is not acceptable.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Within the spectrum of frontotemporal lobar degeneration (FTLD), primary progressive aphasia (PPA) represents a group of disorders where language deficits are the predominant feature. When agrammatic aphasia\u2014characterized by effortful, halting speech and grammatical errors\u2014is present, the clinical picture is most consistent with the nonfluent/agrammatic variant of PPA. The nonfluent/agrammatic variant of PPA is associated with left frontal lobe atrophy, particularly involving Broca\u2019s area. This region\u2019s degeneration disrupts normal language production and the formulation of grammatically correct sentences, leading to agrammatism. Patients with the nonfluent/agrammatic variant of PPA exhibit difficulties in speech production, including slow, effortful, and halting speech with grammatical errors, despite relative preservation of word comprehension. Although these patients fall under the broader FTD spectrum, their presentation is dominated by language dysfunction rather than behavioral issues. Diagnosis is achieved via detailed language and neuropsychological assessments complemented by neuroimaging (MRI and PET). The imaging typically shows focal atrophy in the left frontal lobe and surrounding language areas. Differential diagnoses include the semantic variant of PPA\u2014which primarily affects word comprehension\u2014and the logopenic variant (more commonly associated with Alzheimer\u2019s pathology). Management is primarily supportive, focusing on speech and language therapy to help maintain communication skills. Pharmacologic treatments are limited, though some trials have looked at the potential benefits of medications targeting tau pathology. In rare cases of early-onset PPA where the patient is of childbearing age, any pharmacotherapy during pregnancy or lactation must be carefully assessed for safety. Given the clinical scenario where imaging is similar to FTD but the patient presents with agrammatic aphasia, the correct diagnosis is the nonfluent/agrammatic variant of primary progressive aphasia. The marked answer (Option B) is correct if it represents this diagnosis, as Option A (which is unclear, 'I forgot') is not acceptable. 1. Agrammatism\u2014a hallmark of the nonfluent/agrammatic variant of primary progressive aphasia\u2014is characterized by effortful and grammatically simplified speech. 2. Focal left frontal lobe atrophy on imaging is a key diagnostic clue in differentiating this variant from other forms of PPA and dementia. Recent research continues to explore biomarker development for PPA variants, with an increasing emphasis on the role of tauopathies. Current studies highlight the benefits of early and tailored speech therapy interventions and are investigating potential disease-modifying therapies.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Gerstmann syndrome",
    "option_a": "Angular gyrus",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Gerstmann syndrome is a neuropsychological disorder characterized by a tetrad of symptoms: dysgraphia (difficulty writing), dyscalculia (difficulty with mathematical calculations), finger agnosia (inability to recognize one\u2019s own fingers), and left-right disorientation. It is most commonly associated with lesions affecting the dominant (usually left) parietal lobe, specifically the angular gyrus. Lesions in the angular gyrus disrupt the complex integration of sensory information needed for spatial orientation and symbolic processing. The damage impairs neural networks involved in visuospatial perception and conceptualization, leading to the clinical constellation seen in Gerstmann syndrome. Vascular insults (such as strokes), traumatic injuries, or degenerative processes are typical underlying causes. Patients with Gerstmann syndrome may present with isolated deficits such as difficulty with writing and arithmetic, problems with finger recognition, and challenges in distinguishing left from right. These symptoms directly correlate with the dysfunction of the angular gyrus, a critical hub for integrating sensory inputs and language-related tasks. Diagnosis is primarily clinical, based on the recognition of the characteristic symptom cluster. Neuroimaging, especially MRI, is used to confirm the location of the lesion in the angular gyrus. Differential diagnoses include other parietal lobe syndromes such as Balint\u2019s syndrome or conduction aphasia, which have distinct clinical profiles. Management focuses on treating the underlying cause. In the case of an acute stroke, standard stroke management protocols apply (e.g., thrombolysis when within the therapeutic window, antiplatelet therapy, and supportive care). In traumatic or degenerative cases, rehabilitation therapies (such as occupational and speech therapy) are important. Pregnancy or lactation status may impact the choice of neuroimaging and pharmacotherapy\u2014 for example, ensuring that any radiological studies are performed with appropriate shielding and that medications are chosen in accordance with pregnancy safety profiles. Option A (Angular gyrus) is correct because lesions in the angular gyrus are the classic anatomical correlate of Gerstmann syndrome. Other options, if provided, would either refer to different anatomical regions or lack the specific association with the syndrome\u2019s symptomatology. 1. Gerstmann syndrome is defined by a tetrad: dysgraphia, dyscalculia, finger agnosia, and left-right disorientation. 2. It is typically due to a lesion in the dominant (usually left) angular gyrus. 3. A careful neurological exam and targeted imaging are key to diagnosis. Recent research emphasizes the role of advanced neuroimaging (including diffusion tensor imaging) to better characterize damage in patients with parietal lobe syndromes. Updated stroke management guidelines reinforce the importance of rapid intervention, which indirectly aids in reducing the incidence of focal deficits such as those seen in Gerstmann syndrome.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Old man came with a one-week history of confusion, CBC and electrolytes are normal, Brain CT is unremarkable. What will explain his presentation?",
    "option_a": "Other systemic disorders",
    "option_b": "LP",
    "option_c": "EEG",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Dementia",
    "explanation": "In an elderly patient with acute confusion and normal laboratory and CT findings, it is imperative to consider conditions that may not be immediately apparent on structural imaging. Nonconvulsive seizures, particularly nonconvulsive status epilepticus, are a key consideration. Nonconvulsive seizures involve abnormal electrical discharges within the brain without overt motor manifestations. In older adults, these may present primarily with cognitive changes such as confusion or altered mental status. The underlying mechanism is the transient interruption of normal neuronal activity due to epileptiform discharges. The patient\u2019s presentation of a one-week history of confusion with normal CBC, electrolytes, and an unremarkable CT points toward a functional rather than structural disturbance. Nonconvulsive status epilepticus is one condition that can produce this picture, and it is not detected by CT because it does not cause gross anatomical changes. After ruling out metabolic, infectious, and structural causes, an electroencephalogram (EEG) is indicated to identify abnormal epileptiform activity. Differential diagnoses include metabolic encephalopathy, toxic ingestion, or central nervous system infections (which might require lumbar puncture), but these are less likely given normal lab tests and imaging. Once nonconvulsive seizures are detected via EEG, management includes prompt initiation of antiepileptic medications. First-line agents often include benzodiazepines (e.g., lorazepam) for acute treatment, followed by agents such as levetiracetam for longer-term management. In pregnant or lactating women, levetiracetam is generally considered safe, but individual agents must be chosen with attention to their risk profiles and potential teratogenicity. Option A (Other systemic disorders) is less likely given the normal lab work-up; Option B (LP) would be warranted if an infectious or inflammatory central nervous system process was suspected, but there are no accompanying signs of meningitis or encephalitis; Option C (EEG) is the best diagnostic test to evaluate for nonconvulsive seizures and is therefore the correct response. 1. In unexplained confusion with a normal CT scan, always consider nonconvulsive seizures, especially in the elderly. 2. EEG is the gold standard for diagnosing seizure-related cognitive changes. 3. Early identification and treatment can significantly improve outcomes in nonconvulsive status epilepticus. Recent guidelines stress the importance of EEG in the workup of unexplained altered mental status in elderly patients. Emerging research continues to refine the diagnostic criteria for nonconvulsive seizures, emphasizing rapid diagnosis and early intervention to optimize neurological outcomes.",
    "exam_year": "2020",
    "exam_type": "Part I",
    "image_url": "page_11.png"
  },
  {
    "question": "Feature of Wernicke's encephalopathy what is the type of memory impaired",
    "option_a": "(Immediate memory) is correct as Wernicke's encephalopathy primarily disrupts circuits involved in short",
    "option_b": "(Episodic memory) pertains more to Korsakoff syndrome, the chronic evolution of untreated Wernicke\u2019s. Option c (Procedural memory) is incorrect because procedural memory involves basal ganglia circuits, which are usually spared in this condition.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Dementia",
    "explanation": "Wernicke's encephalopathy is an acute neurological disorder resulting from thiamine (vitamin B1) deficiency. It is classically identified by the triad of ophthalmoplegia, ataxia, and confusion, and is primarily associated with alcohol misuse, though it can also occur in malnourished states. The deficiency in thiamine leads to neuronal dysfunction particularly in structures such as the mammillary bodies, medial thalami, and periaqueductal region. This disruption affects circuits involved in memory formation \u2013 especially the Papez circuit \u2013 resulting in impairment of immediate (short-term) memory processing. In the acute phase of Wernicke\u2019s encephalopathy, patients show significant impairment in immediate memory\u2014that is, the ability to encode and temporarily store new information. Although episodic memory is more severely affected in Korsakoff syndrome (a chronic sequela of inadequately treated Wernicke\u2019s encephalopathy), immediate memory deficits are the hallmark in the acute stage. Diagnosis is primarily clinical, supported by history and examination. MRI can reveal typical signal changes in affected areas, and measurement of blood thiamine levels can be helpful though not always readily available. Differential diagnoses include other causes of encephalopathy such as hepatic encephalopathy, hypoglycemia, and infectious encephalitis; however, the combination of symptoms along with risk factors (e.g., chronic alcoholism) usually points toward Wernicke's encephalopathy. Immediate treatment involves the prompt administration of thiamine, typically intravenously, before any glucose is given to avoid exacerbating the condition. First-line management is high-dose thiamine replacement. In pregnancy or lactation, thiamine is safe and should be administered promptly, particularly in settings like hyperemesis gravidarum where deficiency risk is increased. Subsequent management includes nutritional rehabilitation and addressing underlying risk factors. Option a (Immediate memory) is correct as Wernicke's encephalopathy primarily disrupts circuits involved in short-term information encoding. Option b (Episodic memory) pertains more to Korsakoff syndrome, the chronic evolution of untreated Wernicke\u2019s. Option c (Procedural memory) is incorrect because procedural memory involves basal ganglia circuits, which are usually spared in this condition. 1. Always administer thiamine before glucose in at-risk patients to prevent or treat Wernicke\u2019s encephalopathy. 2. Immediate memory impairment is a key feature in the early stage of the disease. 3. Early recognition and treatment are essential to prevent progression to the more chronic and debilitating Korsakoff syndrome. Recent studies highlight the critical window for thiamine administration to prevent irreversible damage. Updated practice guidelines recommend high-dose IV thiamine in any suspected case of Wernicke's encephalopathy, particularly among alcohol-dependent individuals and malnourished patients, including pregnant women at risk.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Similar to the previous question but options were:",
    "option_a": "PSEN1",
    "option_b": "No PSEN 2 OR APP",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "This question shifts focus to a genetic aspect related to memory disorders, particularly early-onset familial Alzheimer's disease (AD). Alzheimer's disease, characterized by progressive memory loss and cognitive decline, has both sporadic and familial forms, with familial cases often linked to specific gene mutations. Mutations in genes such as PSEN1 (presenilin 1), PSEN2 (presenilin 2), and APP (amyloid precursor protein) lead to abnormal processing of amyloid precursor protein. PSEN1 mutations, which are the most common cause of familial early-onset AD, result in increased production of the neurotoxic beta-amyloid 42 peptide that aggregates to form amyloid plaques. These plaques are central to the pathogenesis of Alzheimer\u2019s disease. Patients with familial Alzheimer\u2019s disease typically develop symptoms at an earlier age (usually before 65) with prominent memory deficits, particularly in episodic memory, along with other cognitive impairments. A positive family history and rapid progression are important clinical clues that point towards a genetic etiology. Diagnosis of familial Alzheimer\u2019s disease involves a thorough clinical and neuropsychological evaluation, brain imaging (MRI or PET), and may include cerebrospinal fluid analysis for AD biomarkers. Genetic testing is recommended for individuals with a strong family history to identify mutations in PSEN1, PSEN2, or APP. Differential diagnoses include other causes of dementia such as vascular dementia, frontotemporal dementia, and Lewy body dementia, which have different clinical and imaging characteristics. Management of Alzheimer's disease is multifaceted, involving pharmacologic interventions (cholinesterase inhibitors such as donepezil, rivastigmine; NMDA receptor antagonist memantine) and non-pharmacologic strategies tailored to the patient\u2019s needs. In cases of familial AD, genetic counseling plays a crucial role. In pregnant or lactating patients, the use of these cognitive enhancers is approached with caution, and treatment is often deferred or supportive measures are emphasized, as current guidelines recommend individualized risk-benefit assessment. Option A (PSEN1) is the correct choice since PSEN1 is the most commonly implicated gene mutation in familial early-onset Alzheimer\u2019s disease. Option B (No PSEN2 OR APP) is incorrect because, although PSEN1 is common, mutations in PSEN2 and APP are also known contributors to familial AD, albeit less frequently. 1. PSEN1 mutations are the most frequent in early-onset familial Alzheimer\u2019s disease and are associated with increased beta-amyloid 42 production. 2. Genetic testing is indicated in patients with a strong family history of early-onset dementia. 3. Differentiating familial AD from other dementias is essential for tailored management and prognostication. Current research in Alzheimer\u2019s disease focuses on amyloid-targeting therapies and early diagnostic biomarkers. Advances in genetic testing continue to improve early identification of familial cases. Updated guidelines emphasize the importance of personalized management strategies and the need for genetic counseling in families affected by early-onset AD.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Young patient with a history of forgetting things... has family history? Gene?",
    "option_a": "APP",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Early-onset familial Alzheimer\u2019s disease is an autosomal dominant dementia that typically causes memory impairment at a younger age (often between 30 and 60 years). The condition is linked to mutations in certain genes that alter amyloid processing. Although mutations in the amyloid precursor protein (APP) gene (Option A) are recognized, the most common genetic mutation in familial early\u2010onset Alzheimer\u2019s disease is found in the presenilin\u20101 (PSEN1) gene \u2013 which is represented here as Option B. Mutations in PSEN1 affect the gamma-secretase complex, leading to aberrant cleavage of the APP protein. This results in an increased production of the amyloid-\u03b242 peptide, which aggregates into amyloid plaques\u2014a hallmark pathology in Alzheimer\u2019s. Genetic studies have consistently shown PSEN1 mutations to be the predominant cause of autosomal dominant early-onset Alzheimer\u2019s disease. Patients with PSEN1 mutations typically present with progressive memory loss and other cognitive deficits at a relatively young age, often with a clear family history of dementia. The clinical scenario of a young patient with forgetfulness and familial predisposition strongly supports a genetic form of Alzheimer\u2019s disease. The diagnosis is made based on clinical findings, family history, neuropsychological testing, and neuroimaging. Genetic testing for PSEN1 (as well as for APP and PSEN2) helps confirm the diagnosis. Differential diagnoses include other types of early-onset dementia such as frontotemporal dementia or vascular dementia, but the autosomal dominant pattern and amyloid pathology are more typical for PSEN1-associated Alzheimer\u2019s. There is no cure for Alzheimer\u2019s disease. Management is symptomatic and supportive. Cholinesterase inhibitors and memantine may be used to help manage cognitive symptoms. In patients of childbearing potential or pregnant/lactating women, careful evaluation of medication risks versus benefits is necessary, and non-pharmacologic supportive care is particularly emphasized. Genetic counseling is recommended for these families. Option A (APP) is a known gene associated with early-onset Alzheimer\u2019s but is less common than PSEN1. Since the marked answer (B) is presumed to represent PSEN1, it is the best choice in this context. Options C and D were not provided. 1. PSEN1 mutations account for the majority of familial early-onset Alzheimer\u2019s disease. 2. A strong family history in a young patient is a clue to a genetic cause. 3. Genetic counseling is an essential component of management. Recent studies continue to reinforce the predominant role of PSEN1 mutations in familial early-onset Alzheimer\u2019s. Ongoing research into targeted therapies and biomarkers is underway, but current management remains symptomatic and supportive.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a patient with memory problems and homonymous hemianopia.",
    "option_a": "CJD",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Posterior Cortical Atrophy (PCA) is a neurodegenerative syndrome and an atypical variant of Alzheimer\u2019s disease primarily affecting the posterior regions of the brain. Patients often present with visuospatial deficits and, in some cases, memory problems. The presence of a homonymous hemianopia\u2014loss of half of the visual field in both eyes\u2014further implicates involvement of the occipital lobe. In PCA, there is preferential degeneration of the occipito-parietal (posterior) regions. The underlying pathology is usually Alzheimer\u2019s disease, with accumulation of amyloid plaques and tau neurofibrillary tangles, but the distribution is atypical. The degeneration in visual processing areas explains the visual field defects, while involvement of adjacent regions may contribute to memory difficulties. Patients with PCA typically present with visual complaints such as difficulty reading, problems with depth perception, and sometimes visual field deficits such as homonymous hemianopia. Over time, they may also develop memory and other cognitive deficits as the disease progresses, making PCA a diagnostic consideration in a patient with both memory issues and specific visual field defects. The differential diagnosis includes occipital lobe stroke, space-occupying lesions (e.g., tumors) in the occipital region, and other neurodegenerative conditions (like Creutzfeldt-Jakob disease [CJD]). Neuroimaging (MRI) demonstrating atrophy in posterior cortical areas helps in diagnosing PCA, while visual field testing (perimetry) can document the hemianopic deficits. CJD typically presents with rapid progression, myoclonus, and other neurological signs that help differentiate it from PCA. There is no cure for PCA. The mainstay of treatment is symptomatic management, which includes cognitive rehabilitation, vision therapy, and occupational therapy to help cope with visual deficits. Cholinesterase inhibitors may be considered based on Alzheimer\u2019s guidelines, though their efficacy in PCA is not robustly proven. In pregnant or lactating patients, non-pharmacological and rehabilitative approaches are preferred owing to safety profiles. Option A (CJD) is not correct because Creutzfeldt-Jakob disease is characterized by rapidly progressive dementia, myoclonus, and cerebellar signs rather than focal visual field deficits like homonymous hemianopia. The marked answer (B), assumed to represent Posterior Cortical Atrophy, is the most appropriate given the clinical presentation. Options C and D were not provided. 1. PCA is an atypical, predominantly visual variant of Alzheimer\u2019s disease. 2. Homonymous hemianopia in a neurodegenerative context should prompt evaluation of posterior cortical regions. 3. Neuroimaging is key to differentiating PCA from other causes of visual deficits. Recent guidelines highlight the importance of a multidisciplinary approach in managing PCA, with emphasis on visual rehabilitation and supportive care. Studies continue to evaluate the role of Alzheimer\u2019s medications in atypical presentations, although evidence remains limited.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a patient with a history of progressive worsening of his language ending with minimum verbal output (either q insufficient or Answer Wrong)",
    "option_a": "Semantic Dementia",
    "option_b": "Primary progressive aphasia",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Primary Progressive Aphasia (PPA) is a neurodegenerative syndrome primarily characterized by gradual deterioration of language capabilities. It encompasses a group of disorders in which language functions decline while other cognitive domains remain relatively preserved, at least in the early stages. PPA results from neurodegeneration affecting the language-dominant regions of the brain, typically in the left hemisphere, including the perisylvian cortex. Within PPA, there are distinct subtypes. The nonfluent/agrammatic variant\u2014characterized by effortful, halting speech and diminished verbal output\u2014is consistent with the presentation described. In contrast, the semantic variant typically shows fluent yet empty speech with impaired comprehension. The described clinical scenario (progressive worsening of language leading to minimal verbal output) is most consistent with the nonfluent/agrammatic variant of PPA. Patients initially struggle with word finding and syntax, and as the disease progresses, speech output becomes markedly reduced. Diagnosis is based on a detailed language evaluation, neuropsychological testing, and neuroimaging (often revealing atrophy in the left perisylvian region). Differential diagnoses include stroke-induced aphasia, other dementias with language involvement (such as certain presentations of frontotemporal dementia), and less commonly, Alzheimer\u2019s disease where language impairment may occur later in the course. Management is primarily supportive and involves speech and language therapy, which can help maximize communication and implement compensatory strategies. There is no disease\u2010modifying therapy for PPA. Medications such as cholinesterase inhibitors (e.g., donepezil) have not consistently demonstrated benefit in PPA. For pregnant or lactating patients, non-pharmacologic interventions (speech therapy, supportive care) are especially appropriate due to the lack of proven pharmacological treatments. Option A (Semantic Dementia) is characterized by fluent speech with loss of word meaning and comprehension deficits, which does not match the described minimal verbal output. The marked answer (B) \u2013 Primary Progressive Aphasia \u2013 correctly encompasses the syndrome, particularly the nonfluent/agrammatic variant. The other options were not provided. 1. In PPA, the nonfluent/agrammatic variant is characterized by decreasing verbal output and agrammatism. 2. Early referral to speech-language therapy is essential. 3. Differentiating between PPA variants is vital for prognostication and management. Current research emphasizes the heterogeneous nature of PPA and the need for early, individualized speech and language interventions. Although pharmacologic options remain limited, ongoing studies are investigating potential therapies, including those targeting specific proteinopathies.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Same as above Q, asked about the treatment?",
    "option_a": "donepezil",
    "option_b": "Reassurance",
    "option_c": "SSRI",
    "option_d": "was not provided.",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "There is currently no approved disease\u2010modifying treatment for Primary Progressive Aphasia (PPA). Instead, treatment focuses on symptomatic management and supportive care. This approach is sometimes summarized as 'reassurance' in the context of the absence of effective pharmacological interventions. PPA involves progressive neurodegeneration of language networks in the brain, notably in the left perisylvian cortex. Because the underlying pathology is degenerative and currently irreversible, therapeutic strategies are largely aimed at coping with declining language ability rather than halting the disease process. Patients with PPA typically present with gradually worsening language function, and as the disease advances, they have significantly reduced verbal output. Since no medication has been shown to alter this course reliably, management centers on supportive measures. After confirming the diagnosis via clinical evaluation, neuropsychological testing, and neuroimaging, the emphasis is placed on rehabilitative measures. It is important to differentiate PPA from other dementias, such as typical Alzheimer\u2019s disease, where cholinesterase inhibitors might be more applicable. The first-line management strategy in PPA is speech and language therapy, along with cognitive and occupational therapies, to help maximize communication and quality of life. Pharmacologic agents such as donepezil (Option A) have not shown consistent benefit in altering the disease course in PPA. SSRIs (Option C) are reserved for cases with significant mood disturbances. In pregnant or lactating women, non-pharmacological interventions are preferred due to the potential risks associated with medications. Option A (donepezil) is primarily used in Alzheimer\u2019s disease and lacks proven efficacy in PPA. Option C (SSRI) may be helpful only if there is comorbid depression or behavioral issues. The marked answer (B) \u2013 Reassurance \u2013 emphasizes that, in the absence of disease-modifying treatments, a supportive approach (often involving reassurance and the initiation of speech therapy) is the best current strategy. Option D was not provided. 1. PPA currently has no proven pharmacologic treatment to halt progression. 2. Early engagement with speech-language therapy is key to managing symptoms. 3. Supportive care and patient (and family) education is central to management. Recent studies and guidelines have underscored that while cholinesterase inhibitors benefit Alzheimer\u2019s disease patients, their efficacy in PPA is unproven. Current research continues to explore potential therapeutic targets, but for now, multidisciplinary rehabilitative care remains the standard.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of an old patient with episodic memory problems forgetting places, can't drive to and can't manage her appointments. can't retain new information, but no behavioral issues and able to recall everything from his past (If affected his daily living so consider Alzheimer and to start treatment / if not affected daily activities so MCI and reassurance)",
    "option_a": "Alzheimer disease",
    "option_b": "MCI",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "This case distinguishes Alzheimer\u2019s dementia from Mild Cognitive Impairment (MCI) based on the impact on daily activities. In Alzheimer\u2019s dementia, memory loss is severe enough to interfere with instrumental activities of daily living (IADLs) such as driving and managing appointments, while in MCI these functions are generally preserved. Alzheimer\u2019s disease is characterized by extracellular amyloid-beta plaques and intracellular neurofibrillary tau tangles that lead to synaptic dysfunction and neuronal loss. Early pathological change is typically seen in the hippocampus, crucial for memory formation, which then progresses to other cortical regions. Patients with Alzheimer\u2019s dementia often exhibit prominent deficits in recent memory, as seen with forgetting new information. The impairment in managing complex tasks (driving, appointments) directly correlates with the degeneration in brain regions responsible for executive function and memory consolidation. Diagnosis is primarily clinical, supported by cognitive assessments such as the Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA). Neuroimaging (MRI/CT) can help rule out reversible causes, while biomarkers (CSF amyloid/tau) may support the diagnosis in uncertain cases. Differential diagnoses include other neurodegenerative disorders, vascular dementia, and depression-related pseudodementia. First-line management includes cholinesterase inhibitors (donepezil, rivastigmine, galantamine) in mild-to-moderate stages and memantine in moderate-to-severe cases, alongside nonpharmacologic approaches such as cognitive rehabilitation and caregiver support. While the patient in this scenario is older and not of reproductive age, pregnancy and lactation considerations are crucial in younger patients where drug safety categories must be rigorously applied. Option A (Alzheimer disease) is appropriate because the patient\u2019s inability to manage daily tasks (driving, appointments) suggests dementia rather than MCI. Option B (MCI) would be applicable if the patient\u2019s daily activities were not affected. 1) The transition from MCI to Alzheimer\u2019s disease is marked by interference with daily activities. 2) Memory loss in Alzheimer\u2019s typically begins with short-term memory and progressively affects other cognitive domains. Recent guidelines emphasize early diagnosis and multidisciplinary management. Emerging biomarkers and neuroimaging techniques are increasingly used to support clinical evaluation, and therapeutic research continues to explore disease-modifying agents for Alzheimer\u2019s disease.",
    "exam_year": "2021",
    "exam_type": "Part I"
  }
]